DHX9 inhibitor and pharmaceutical use thereof
By synthesizing DHX9 inhibitor compounds, the problem of selective inhibition of tumors with BRCA loss of function and mismatch repair defects in existing technologies has been solved, achieving effective treatment of a variety of tumors and enhancing immunotherapy.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD
- Filing Date
- 2025-12-30
- Publication Date
- 2026-07-09
AI Technical Summary
Current technologies have not effectively utilized DHX9 as a target for tumor therapy, especially in tumors with BRCA loss of function and mismatch repair defects, where the lack of selective inhibitors leads to limited therapeutic effects.
A class of DHX9 inhibitor compounds were designed and synthesized. Through the combination of specific structural units, they selectively inhibit the activity of DHX9, interfere with its function in tumor cells, induce S-phase arrest and apoptosis, enhance the immunogenic tumor microenvironment, and enhance the response to ICB therapy.
It achieves selective inhibition of various tumors such as BRCA-mutated breast cancer, ovarian cancer, and colorectal cancer, reduces tumor growth, enhances the effect of immunotherapy, and has no significant toxicity to normal cells.
Smart Images
Figure CN2025147366_09072026_PF_FP_ABST